- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04022967
ANRS 12372 MODERATO Study (MODERATO)
Randomized, Non-inferiority Trial Comparing a Dual Maintenance Therapy Strategy With Dolutegravir + Lamivudine (DTG/3TC) or Atazanavir/Ritonavir + Lamivudine (ATV/r+3TC) Versus the Standard WHO First Line Triple Therapy Tenofovir + Lamivudine + Efavirenz (TDF+3TC+EFV) or Dolutegravir + Lamivudine + Tenofovir (DTG+3TC+TDF) in West and Central African HIV-1 Infected Patients
MODERATO is a phase III, open-label, randomized, multicenter, non-inferiority trial conducted in West and Central Africa (Cameroon, Côte d'Ivoire, Burkina Faso).
HIV-1 infected adults receiving first line ART with TDF+XTC+EFV or DTG+XTC+TDF virologically suppressed will be recruited and followed during 100 weeks.
The objective is to assess the non-inferiority of a strategy consisting of switching to a dual maintenance therapy (DTG+3TC or ATV/r+3TC), comparing to WHO standard first line regimen (TDF+3TC+EFV or DTG+3TC+TDF), in terms of virological success at 96 weeks
Study Overview
Status
Conditions
Detailed Description
In HIV-1 infected adults receiving first line ART with TDF+XTC+EFV or DTG+XTC+TDF virologically suppressed (viral load < detection limit of the technique used) for at least two years: to assess the non-inferiority of a strategy consisting of switching to a dual maintenance therapy (DTG+ 3TC or ATV/r+3TC), comparing to WHO standard first line regimen (TDF+3TC+EFV or DTG+3TC+TDF), in terms of virological success at 96 weeks, in Cameroon, Côte d'Ivoire and Burkina Faso.
This is a trial including two strategies (dual maintenance therapy and triple reference therapy) and three ART regimens (DTG+3TC and ATV/r+3TC used in the maintenance strategy and TDF+3TC+EFV/ DTG+3TC+TDF used in the reference strategy).
The primary analysis will compare the two strategies. Secondary analyses will compare the three ART regimens two by two.
In order to make these secondary analyses possible, participants will be randomly assigned, at inclusion, to each of the three ART regimens (arm 1: DTG+3TC; arm 2: ATV/r+3TC; arm 3: TDF+3TC+EFV / DTG+3TC+TDF). The maintenance strategy will include arm 1 and 2. The reference strategy will include arm 3
Number of participants : 480 (160 in each ART regimen, ie 320 in the dual maintenance therapy strategy and 160 in the triple therapy reference strategy)
The primary endpoint is treatment success, as defined by using the FDA snapshot algorithm : patients who are still continuing the assigned strategy and whose last available plasma HIV-1 RNA in the the window analysis (90 to 102 weeks) is <50 copies/ml at the end of the window analysis (90 to 102 weeks)
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Fadiga Fatoumata, MD
- Phone Number: +225 21755960
- Email: fatoumata.fadiga@pacci.ci
Study Contact Backup
- Name: Raoul Moh, MD, PhD
- Phone Number: +225 21755960
- Email: raoul.moh@pacci.ci
Study Locations
-
-
-
Bobo-Dioulasso, Burkina Faso
- Hôpital de jour, Service des maladies infectieuses, CHU Sourô Sanou
-
Ouagadougou, Burkina Faso
- Service de médecine interne, CHU Yalgado Ouédraogo
-
-
-
-
-
Yaoundé, Cameroon
- Service des Maladies Infectieuses, Hôpital du jour, Hôpital Central
-
-
-
-
-
Abidjan, Côte D'Ivoire
- Centre de Prise en Charge et de Formation (CePReF), Association ACONDA
-
Abidjan, Côte D'Ivoire
- Service des Maladies Infectieuses et Tropicales (SMIT), CHU de Treichville
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- HIV-1 infection
- Age of legal majority
- CD4 > 200 cells/mm3 at pre-inclusion
- Start first-line ART with non-nucleotide reverse transcriptase inhibitors including TDF+XTC+EFV for at least two years without a past history of virological failure, OR
- Be on TDF+XTC+EFV for at least two years then DTG+XTC+TDF without a past history of virological failure, OR
- Be on DTG+XTC+TDF (1st line regimen) for at least two years without a past history of virological failure
- Absence of past history of virological failure (viral load above the threshold corresponding to the test used); two blips between 50 and 200 copies/ml are allowed.
- At least 2 consecutive HIV-1 RNA < 50 copies/ml within past 2 years, including HIV-1 RNA at pre-inclusion
- Women with pregnancy potential are required to use an effective contraceptive method throughout the study follow up.
- Signed informed consent
Exclusion Criteria:
- HIV-2 infection or HIV-1+2 infection
- CD4 nadir <100 cells/mm3
- Chronic Hepatitis B (HBs Ag positive in the pre-inclusion balance)
- Ongoing active Tuberculosis
- Ongoing severe opportunistic infection
- Ongoing chemotherapy or immunotherapy
- Grade > 2 hemoglobin, neutrophil or platelet disorder
- ALT≥ 3 times the upper limit of normal value
- Creatinine clearance < 50 ml/min (CKD-EPI)
- Allergy to a trial drugs or drug component
- Ongoing pregnancy or Refusal of contraception
- Patient at risk of non-compliance
- Ongoing treatment with a drug that should not be associated with one of the drugs used in the study (cf appendix E page 77)
- Any symptoms or biological findings suggestive of a systemic disorder (renal, hepatic, cardiovascular, pulmonary) or other medical conditions that may interfere with the interpretation of test results or jeopardize the health of patients
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1 : Dual maintenance therapy DTG+3TC
|
One daily tablet (50mg) during 96 weeks
One daily tablet (300mg) during 96 weeks
|
Experimental: Arm 2 : Dual maintenance therapy ATV/r+3TC
|
One daily tablet (300mg) during 96 weeks
One daily tablet with atazanavir (300 mg) boosted with ritonavir (100 mg) during 96 weeks
|
Active Comparator: Arm 3 : Reference triple therapy TDF+3TC+EFV or DTG+3TC+TDF
|
One daily tablet with tenofovir 245 mg + lamivudine (300 mg) + efavirenz (400 mg) during 96 weeks OR One daily tablet with dolutegravir 50 mg + lamivudine (300 mg) + tenofovir (300 mg) during 96 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The treatment success, as defined by using the FDA snapshot algorithm
Time Frame: 90 to 102 weeks
|
Success : The proportion of patients who are still continuing the assigned strategy and whose last available plasma HIV-1 RNA in the the window analysis is <50 copies/ml at the end of the window analysis. Failure : patients who have discontinued the assigned strategy or whose last available plasma HIV-1 RNA in the window analysis (90 to 102 weeks) is ≥ 50 copies/ml or with no available HIV-1 RNA in the window analysis |
90 to 102 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Failure combined endpoint
Time Frame: Between Day 0 and Week 96
|
Percentage of participants who reach the following combined endpoint : "new drug-resistant resistance mutations observed", "decline of at least 20% in creatinine clearance" and "occurrence of at least one grade 3-4 neuropsychiatric disorder"
|
Between Day 0 and Week 96
|
Plasma HIV-1 RNA
Time Frame: Between Day 0 and Week 96
|
Evolution of plasma HIV-1 RNA
|
Between Day 0 and Week 96
|
Virological success
Time Frame: Between Day 0 and Week 96
|
Evolution of the percentage of participants with virological success (VL< 50 copies/Ml)
|
Between Day 0 and Week 96
|
CD4 lymphocyte
Time Frame: Between Day 0 and Week 96
|
Evolution of CD4 lymphocyte absolute count and percentage
|
Between Day 0 and Week 96
|
Virological failure and new resistance mutations
Time Frame: Week 48 and Week 96
|
Percentage of participants with virological failure and new resistance mutations
|
Week 48 and Week 96
|
New HIV-1 drug resistance mutations
Time Frame: Week 48 and Week 96
|
Profile of new HIV-1 drug resistance mutations observed in participants with virological failure
|
Week 48 and Week 96
|
WHO stage 3-4 morbidity
Time Frame: Between Day 0 and Week 96
|
Incidence of WHO stage 3-4 morbidity ( AIDS events and non AIDS severe morbidity)
|
Between Day 0 and Week 96
|
ANRS grade 3-4 overall morbidity
Time Frame: Between Day 0 and Week 96
|
Incidence of ANRS grade 3-4 overall morbidity (toxicity)
|
Between Day 0 and Week 96
|
ANRS grade 3-4 renal morbidity
Time Frame: Between Day 0 and Week 96
|
Incidence of ANRS grade 3-4 renal morbidity
|
Between Day 0 and Week 96
|
ANRS grade 3-4 neurologic morbidity
Time Frame: Between Day 0 and Week 96
|
Incidence of ANRS grade 3-4 neurologic morbidity
|
Between Day 0 and Week 96
|
ANRS grade 3-4 hepatic morbidity
Time Frame: Between Day 0 and Week 96
|
Incidence of ANRS grade 3-4 hepatic morbidity
|
Between Day 0 and Week 96
|
Creatinine clearance
Time Frame: Between Day 0 and Week 96
|
Evolution of creatinine clearance
|
Between Day 0 and Week 96
|
Grade 1,2,3 or 4 renal disorders
Time Frame: Between Day 0 and Week 96
|
Evolution of the percentage of patients with grade 1,2,3 or 4 renal disorders
|
Between Day 0 and Week 96
|
Grade 1,2,3 or 4 hepatic liver disorders or abnormalities
Time Frame: Between Day 0 and Week 96
|
Evolution of the percentage of patients with grade 1,2,3 or 4 hepatic liver disorders or abnormalities
|
Between Day 0 and Week 96
|
Grade 1,2,3 or 4 CNS disorders
Time Frame: Between Day 0 and Week 96
|
Evolution of the percentage of patients with grade 1,2,3 or 4 CNS disorders
|
Between Day 0 and Week 96
|
Bone mineral density
Time Frame: Between Day 0 and Week 96
|
Evolution of bone mineral density measured using CT bone density scan
|
Between Day 0 and Week 96
|
Adherence to treatment using a self-questionnaire
Time Frame: Between Day 0 and Week 96
|
Evolution of adherence to treatments measured using a self-questionnaire
|
Between Day 0 and Week 96
|
Life quality
Time Frame: Between Day 0 and Week 96
|
Evolution of quality of life measured using the ProQOL questionnaire
|
Between Day 0 and Week 96
|
Symptoms
Time Frame: Between Day 0 and Week 96
|
Evolution of symptoms using the "symptoms experienced" questionnaire
|
Between Day 0 and Week 96
|
ARV drug plasma concentrations in participants with treatment failure
Time Frame: Between Day 0 and Week 96
|
ARV drug plasma concentrations in participants with treatment failure
|
Between Day 0 and Week 96
|
Switched back to triple therapy
Time Frame: Between Day 0 and Week 96
|
Percentage of patients on dual therapy who switched back to triple therapy
|
Between Day 0 and Week 96
|
Cost-effectiveness of the 3 ARV strategies
Time Frame: Week 96
|
Cost-effectiveness of the 3 ARV strategies
|
Week 96
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Serge P. Eholié, MD, MSc, Pr, Service des Maladies Infectieuses et Tropicales, CHU de Treichville, Abidjan, Côte d'Ivoire
- Principal Investigator: Roland Landman, MD, Institut de Médecine et d'Epidémiologie Appliquée - Hôpital Bichat Claude Bernard, Paris, France
- Study Director: Xavier Anglaret, MD, PhD, Inserm 1219, Université de Bordeaux, France
- Study Chair: Pierre-Marie Girard, MD, PhD, Infectious Diseases Department, University Hospital Saint Antoine, Paris, France
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Protease Inhibitors
- Cytochrome P-450 CYP3A Inhibitors
- Cytochrome P-450 Enzyme Inhibitors
- Cytochrome P-450 Enzyme Inducers
- Cytochrome P-450 CYP3A Inducers
- HIV Integrase Inhibitors
- Integrase Inhibitors
- HIV Protease Inhibitors
- Viral Protease Inhibitors
- Cytochrome P-450 CYP2B6 Inducers
- Cytochrome P-450 CYP2C9 Inhibitors
- Cytochrome P-450 CYP2C19 Inhibitors
- Tenofovir
- Ritonavir
- Lamivudine
- Atazanavir Sulfate
- Efavirenz
- Dolutegravir
Other Study ID Numbers
- ANRS 12372 MODERATO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV-1-infection
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Helios SaludViiV HealthcareUnknownHiv | HIV-1-infectionArgentina
-
Frontier Biotechnologies Inc.RecruitingHIV-1-infectionUnited States
-
University of ZurichActive, not recruitingHIV-1-infectionSwitzerland
-
MacroGenicsNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1-infectionUnited States
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Aelix TherapeuticsCompleted
-
University of North Carolina, Chapel HillNational Institute of Allergy and Infectious Diseases (NIAID)CompletedHIV-1 InfectionUnited States
-
Taipei Veterans General Hospital, TaiwanCompleted
-
Shanghai Public Health Clinical CenterUnknown
-
Fundación FLS de Lucha Contra el Sida, las Enfermedades...Completed
Clinical Trials on dolutegravir
-
ViiV HealthcareGlaxoSmithKlineCompletedHIV InfectionsUnited States
-
ViiV HealthcareCompleted
-
University of KwaZuluCentre for the AIDS Programme of Research in South AfricaRecruitingTuberculosis | HivSouth Africa
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompletedInfections, Human Immunodeficiency Virus and HerpesviridaeUnited States
-
ViiV HealthcareGlaxoSmithKline; ShionogiCompleted
-
National Institute of Allergy and Infectious Diseases...Eunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingHIVUnited States, Brazil, Puerto Rico, South Africa, Thailand
-
Fundación HuéspedViiV HealthcareCompletedHIV-1 InfectionArgentina
-
Thomas BenfieldRecruitingCardiovascular Diseases | HIV Infections | Hiv | Weight Change, Body | HIV Lipodystrophy | HIV CardiomyopathyDenmark
-
ViiV HealthcareGlaxoSmithKlineCompletedInfection, Human Immunodeficiency VirusUnited States